Blood Pressure Reduction With Dapagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

被引：0
|
作者：
Woo, Vincent [1 ]
Leiter, Lawrence A. [2 ]
Cefalu, William T. [3 ]
de Bruin, Tjerk W. [4 ]
Gause-Nilsson, Ingrid [5 ]
Parikh, Shamik J. [4 ]
Johnsson, Eva [5 ]
机构：
[1] Univ Manitoba, Endocrinol Sect, Winnipeg, MB, Canada
[2] St Michaels Hosp, Div Endocrinol & Metab, Toronto, ON M5B 1W8, Canada
[3] Louisiana State Univ Syst, Pennington Biomed Rsch Cntr, Baton Rouge, LA USA
[4] AstraZeneca, Rsch & Dev, Wilmington, DE USA
[5] AstraZeneca, Rsch & Dev, Molndal, Sweden
来源：
CIRCULATION | 2013年 / 128卷 / 22期
关键词：
Blood pressure; Cardiovascular disease; Clinical trials; Diuretics; Older population;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
10606
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dapagliflozin Lowers Blood Pressure in Patients with Type 2 Diabetes
    Sjostrom, David
    Ptaszynska, Agata
    List, James F.
    Johnsson, Eva
    [J]. DIABETES, 2014, 63 : A613 - A613
  • [2] Blood Pressure Reduction Effect of Dapagliflozin in Patients with Type 2 Diabetes Mellitus: a Systematic Review
    Lee, J. V.
    Sabran, M. Z.
    Rubismo, K. Y.
    Zebua, A.
    Jhoputri, C. F.
    Lee, J. B.
    [J]. JOURNAL OF HYPERTENSION, 2023, 41 (SUPPL 2)
  • [3] BLOOD PRESSURE AND THE RISK OF CARDIOVASCULAR DISEASE AMONG PATIENTS WITH TYPE 2 DIABETES
    Hu, G.
    [J]. CARDIOLOGY, 2014, 128 : 353 - 353
  • [4] Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes
    Al-Bazz, Dalai Y.
    Wilding, John P. H.
    [J]. FUTURE CARDIOLOGY, 2020, 16 (02) : 77 - 88
  • [5] Cardiovascular Outcomes with Dapagliflozin for Patients with Type 2 Diabetes
    Pavlicek, Vojtech
    [J]. DIABETOLOGE, 2019, 15 (03): : 262 - 264
  • [6] Dapagliflozin treatment for type 2 diabetes mellitus patients with a history of cardiovascular disease
    Leiter, L.
    Cefalu, W.
    DeBruin, T.
    Gause-Nilsson, I.
    Sugg, J.
    Parikh, S.
    [J]. DIABETOLOGIA, 2012, 55 : S310 - S311
  • [7] Dapagliflozin lowers blood pressure in hypertensive and nonhypertensive patients with type 2 diabetes
    Sjostrom, D.
    Johansson, P.
    Ptaszynska, A.
    List, J.
    Johnsson, E.
    [J]. DIABETOLOGIA, 2014, 57 : S332 - S333
  • [8] Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
    Avgerinos, Ioannis
    Liakos, Aris
    Tsapas, Apostolos
    Bekiari, Eleni
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2549 - 2557
  • [9] Efficacy and Safety of Dapagliflozin for Type 2 Diabetes Mellitus Patients With a History of Cardiovascular Disease
    Leiter, Lawrence A.
    Cefalu, William T.
    Debruin, Tjerk W.
    Gausenilsson, Ingrid
    Sugg, Jennifer
    Parikh, Shamik J.
    [J]. DIABETES, 2012, 61 : A287 - A287
  • [10] Dapagliflozin Treatment for Type 2 Diabetes Mellitus Patients With Comorbid Cardiovascular Disease and Hypertension
    Cefalu, William T.
    Leiter, Lawrence A.
    Debruin, Tjerk W.
    Gausenilsson, Ingrid
    Sugg, Jennifer
    Parikh, Shamik J.
    [J]. DIABETES, 2012, 61 : A271 - A271
12345